Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP known ✓ | P20292 | 20/20 | 0.78 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.78 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.78 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924847 | 1.00 | ALOX5AP (0.78) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29526863 | 0.95 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1254527 | 0.95 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1394726 | 0.93 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1254870 | 0.93 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL167903 | 0.93 | ALOX5AP (0.90) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL29063029 | 0.93 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL3057387 | 0.91 | ALOX5AP (0.77) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL1722524 | 0.88 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4S | |
| Fiboflapon SCHEMBL29723363 | 0.88 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598925-A1 | CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT | Enanta Pharmaceuticals, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-120077045-A | Crystal form of SARS-resistant COV-2 preparation | 英安塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025090868-A1 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4514805-A1 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4396175-A1 | CRYSTALLINE INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4387980-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4376834-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024107783-A2 | NOVEL MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024076680-A1 | CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023211997-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023009187-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023003610-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022240541-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022235605-A1 | NOVEL MACROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022221686-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-4051265-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022109360-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-114524821-A | Novel spiropyrrolidine derived antiviral drugs | 英安塔制药有限公司 | 2022-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALOX5AP 1808/4885PTGS1 1416/4885ALOX5 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.